TRIM proteins in therapeuticmembrane repair ofMuscular dystrophy

JAMA Neurology

Volumn 70, Issue 7, 2013, Pages 928-931

  Alloush, Jenna ^a,b   Weisleder, Noah ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c TRIM edicine Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITSUGUMIN 53; PEPTIDES AND PROTEINS; RECOMBINANT PROTEIN; TRIPARTITE MOTIF PROTEIN 72; UNCLASSIFIED DRUG; CARRIER PROTEIN; MEMBRANE PROTEIN; MITSUGUMIN 53, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRIM PROTEIN, HUMAN;

ARTICLE; CELL DAMAGE; CELL MEMBRANE; CELL REGENERATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; FUTUROLOGY; GENE; GENE THERAPY; HUMAN; MG53 GENE; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN TARGETING; TREATMENT RESPONSE; DRUG EFFECT; GENETICS; METABOLISM; MUSCLE WEAKNESS; REVIEW;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID MOTIFS; CARRIER PROTEINS; CELL MEMBRANE; HUMANS; MEMBRANE PROTEINS; MUSCLE WEAKNESS; MUSCULAR DYSTROPHIES;

EID: 84880278013     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.469     Document Type: Article

References (10)

1. Bi GQ, Alderton JM, Steinhardt RA. Calcium-regulated exocytosis is required for cell membrane resealing. J Cell Biol. 1995;131(6, pt 2): 1747-1758.
2. McNeil PL, Ito S. Gastrointestinal cell plasma membrane wounding and resealing in vivo. Gastroenterology. 1989;96(5, pt 1):1238-1248.
3. McNeil PL, Steinhardt RA. Plasma membrane disruption: repair, prevention, adaptation. Annu Rev Cell Dev Biol. 2003;19:697-731.
4. Bansal D, Miyake K, Vogel SS, et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature. 2003;423(6936):168-172.
5. Cai C, Masumiya H, Weisleder N, et al. MG53 nucleates assembly of cell membrane repair machinery. Nat Cell Biol. 2009;11(1):56-64.
6. He B, Tang RH, Weisleder N, et al. Enhancing muscle membrane repair by gene delivery of MG53 ameliorates muscular dystrophy and heart failure in ?-sarcoglycan-deficient hamsters. Mol Ther. 2012;20(4):727-735.
7. Weisleder N, Takizawa N, Lin P, et al. Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy. Sci Transl Med. 2012;4(139):139ra85. doi:10. 1126/scitranslmed. 3003921.
8. Lee CS, Yi JS, Jung SY, et al. TRIM72 negatively regulates myogenesis via targeting insulin receptor substrate-1. Cell Death Differ. 2010;17(8):1254- 1265.
9. Burkin DJ, Wuebbles RD. A molecular bandage for diseased muscle. Sci Transl Med. 2012;4(139): 139fs19. doi:10. 1126/scitranslmed. 3004082.
10. Cai C, Weisleder N, Ko JK, et al. Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin. J Biol Chem. 2009;284(5):15894-15902.